Johnson & Johnson’s agrees to a $181 million settlement with 36 states and the District of Columbia over Risperdal, an antipsychotic drug used off label by elderly and children to help with bipolar disorders. The settlement comes after prosecutor said that Johnson and Johnson’s pharmaceutical subsidiary Janssen failed to disclose all of the risks associated with the drug. Janssen stated the settlement was agreed to in order to avoid unnecessary expense and a prolonged legal process, as opposed to an admission of wrongdoing. The company has an additional settlement with the U.S. Justice Department pending. Refer to the New York Times and Philadelphia Inquirer for additional information.